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Spinal neurofibromatosis (SNF) is considered to be an alternative form of neurofibromatosis, showing multiple
spinal tumors and cafe´-au-lait macules. Involvement of the neurofibromatosis type 1 (NF1) locus has been dem-
onstrated, by linkage analysis, for three families with SNF. In one of them, a cosegregating frameshift mutation in
exon 46 of the NF1 gene was identified. In the present study, we report four individuals from two families who
carry NF1 null mutations that would be expected to cause NF1. Three patients have multiple spinal tumors and
no cafe´-au-lait macules, and the fourth has no clinical signs of NF1. In the first family, a missense mutation
(Leu2067Pro) in NF1 exon 33 was found, and, in the second, a splice-site mutation (IVS31-5ArG) enlarging exon
32 by 4 bp at the 5′ end was found. The latter mutation has also been observed in an unrelated patient with
classical NF1. Both NF1 mutations cause a reduction in neurofibromin of ∼50%, with no truncated protein present
in the cells. This demonstrates that typical NF1 null mutations can result in a phenotype that is distinct from
classical NF1, showing only a small spectrum of the NF1 symptoms, such as multiple spinal tumors, but not
completely fitting the current clinical criteria for SNF. We speculate that this phenotype is caused by an unknown
modifying gene that compensates for some, but not all, of the effects caused by neurofibromin deficiency.
Paraspinal nerve-sheath tumors occur solitarily and spo-
radically. Several paraspinal tumors have been observed
in a minority of patients with neurofibromatosis type 1
(NF1 [MIM 162200]) (Huson et al. 1988; McGaughran
et al. 1999; Thakkar et al. 1999). These tumors occur
as a main symptom in familial spinal neurofibromatosis
(SNF [MIM 162210]). Four families with SNF have been
reported to date (Pulst et al. 1991 [two families]; Poy-
honen et al. 1997; Ars et al. 1998); in three of them,
involvement of the NF1 locus has been demonstrated by
linkage analysis. In one family, Ars et al. (1998) iden-
tified a cosegregating frameshift mutation (8042insA),
in exon 46 of the NF1 gene, which is also suggested to
result in a truncated neurofibromin in vivo. All affected
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family members fit the current clinical criteria for SNF,
showing multiple spinal tumors and cafe´-au-lait mac-
ules. In addition, one had cutaneous neurofibromas,
whereas the others showed different signs of NF1. In
the present study, we describe two families with multiple
spinal tumors. The patients show spinal tumors but no
cafe´-au-lait macules. Two of the patients show a few
dermal tumors, histologically identified as neurofibroma
or schwannoma. Other signs of NF1 or NF2 (MIM
101000) are missing in both families. The patients were
examined clinically in the Interdisciplinary Neurofibro-
matosis Clinic of the University of Ulm, and the appro-
priate informed consent was obtained from the patients.
Our investigations determined that twomembers of each
family are heterozygous for NF1 null mutations.
In the first family (NF134), the propositus was a fe-
male aged 32 years (NF134-3). An intrathoracic tumor
was detected in her upper mediastinum, at age 17 years.
The biopsy of the tumor was histologically identified as
neurinoma. In addition, multiple tumors of the cervical
and lumbar spine and of the psoas muscle were detected
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Figure 1 Mutations of NF134-3 and of NF138-3, causing no alteration in the amount of NF1 mRNA (A and B) in relation to the
expression of S14 (C and D). Fibroblasts from NF134-3, NF138-3, and a healthy donor (FC16) were seeded at a density of 4,000 cells/cm2,
were cultured for 2 d, and were total-RNA isolated. For each cell culture, 4# 1 mg RNA was reverse transcribed with random hexamers and
different amounts of standard RNAs for NF1 and S14 and then were PCR amplified with primer pair NF1-H/NF1-R and S14-H/S14-R.
Measurement of the band intensities of the PCR products was performed as described by Kaufmann et al. (1999), with the followingmodification:
the volume of the heteroduplex band was additionally measured, with half of its amount being added to both the volume of the transcript and
the standard band. A, RT-PCR products for measurement of NF1 mRNA amounts, 1 mg of total RNA each: FC16 (lanes 1–4), NF134-3 (lanes
5–8), and NF138-3 (lanes 9–12). The products were separated on a 1.5% agarose gel stained with ethidium bromide. Lower band (345 bp),
NF1 standard; middle band, heteroduplexes; upper band (395 bp), NF1 transcript. Amounts of NF1 standard RNA added: lanes 1, 5, and 9,
5 pg; lanes 2, 6, and 10, 2.5 pg; lanes 3, 7, and 11, 1.25 pg; lanes 4, 8, and 12, 0.625 pg. B, Graphical representation with linear regression
for each of the NF1 mRNA measurements (vol. p integration of the volume of the band areas; T p transcript; S p standard). C, RT-PCR
products for measurement of S14 mRNA amounts, 1 mg of total RNA each: FC16 (lanes 1–4), NF134-3 (lanes 5–8), and NF138-3 (lanes 9–12).
The products were separated on a 1.5% agarose gel stained with SYBR-Gold. Lower band (148 bp), S14 standard; middle band (197 bp), S14
transcript; upper band, heteroduplexes. Amounts of S14 standard RNA added: lanes 1, 5, and 9, 2,000 pg; lanes 2, 6, and 10, 1,000 pg; lanes
3, 7, and 11, 500 pg; lanes 4, 8, and 12, 250 pg. D, Graphical representation with linear regression for each of the S14 mRNA measurements.
Abbreviations are the same as those listed for figure 1B.
by magnetic resonance imaging (MRI) scan. At ages 23
and 27 years, tumors were excised in C6/7 and L2. These
were identified as schwannoma and neurofibroma, re-
spectively. At ages 29 and 32 years, a subcutaneous neu-
rofibroma and a subcutaneous schwannoma, respec-
tively, were excised. During the present investigations,
multiple intradural and intramedullar tumor masses
were detected by MRI scan in all segments of the spine.
Tumors in the central nervous system (CNS) that are
typical of NF2 were not found. The patient did not show
cafe´-au-lait macules, intertrigenous freckling, or Lisch
nodules. The patient, a student, shows no signs ofmental
retardation or scoliosis. Her parents’ (NF134-1 and
NF134-2, aged 60 and 61 years, respectively) medical
history revealed no brain tumors, spinal cord tumors,
neurofibromas, cafe´-au-lait macules, unexplained deaf-
ness, neurological disability, or lumbago. Additional
clinical investigations were not possible.
In the second family (NF138), the female propositus
(NF138-3, aged 31 years), observed multiple painful in-
tradermal tumors on the extremities and the trunk, at
age 17 years. One of these tumors was excised and was
histologically identified as a neurofibroma. Another tu-
mor was excised from the thoracic spine at age 29 years
and was histologically identified as schwannoma. Mul-
tiple spinal tumors currently have been found, through
use of MRI scans, in all segments of the spine, especially
in C5/6. Other symptoms typical for NF1, such as cafe´-
au-lait macules, freckles, Lisch nodules, scoliosis, or tu-
mors of the CNS, were not found. Clinical investigation
of her mother (NF138-2, aged 57 years) revealed two
lumbar hyperpigmentations that were 2 cm in diameter,
without sharp borders. Signs of NF1 or NF2 were not
found. She presented with acute lumbago. TheMRI scan
revealed enlarged spinal nerves from L3/4 to L5/S1. An
additional MRI scan showed these alterations in all seg-
ments of the spine. The anamnesis of her husband
(NF138-1), her son (NF138-4), and her second daughter
(NF138-5) did not reveal symptoms of NF1 or NF2.
NF1 mutation screening, of complementary DNA
(cDNA) as well as of genomic DNA (gDNA), was per-
formed in these families through use of the enzymatic
mutation detection (EMD) method, for all exons (Ei-
senbarth et al. 2000), with subsequent genomic se-
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Figure 2 Reduction in the amount of neurofibromin in fibroblasts of NF134-3 and NF138-3 (A and B). No additional shortened neu-
rofibromin band is detectable in either cell culture (C). A, Detection of neurofibromin in lysates, by western blotting of immunoprecipitated
neurofibromin. Cells were cultured in parallel, were seeded at a density of 4,000 cells/cm2, were cultured for 3 d, and were lysed as described
elsewhere (Griesser et al. 1995). Neurofibromin was immunoprecipitated from equal amounts of total protein (lanes 2–7, 600 mg; lane 8, 300
mg) by incubation with an antibody against the amino-terminal domain of neurofibromin (sc-68; Santa Cruz Biotechnology) for 1.5 h, followed
by incubation with protein-A-Sepharose (Amersham Pharmacia Biotech). The samples were boiled in SDS-sample buffer and were separated
with SDS-PAGE. After blotting on polyvinylidene fluoride (PVDF) membrane, immunodetection was performed using an antibody against the
carboxy-terminal domain of neurofibromin (sc-67; Santa Cruz Biotechnology) and the ECL system. The resulting bands were evaluated using
a video-densitometric system that allows neurofibromin quantification (Griesser et al. 1997; Klose et al. 1998). Lane 1,molecular weight marker,
myosin (220 kD); lanes 2 and 6, fibroblasts from a healthy donor (FC7); lane 3, fibroblasts of NF71 carrying a stop mutation (Stark et al.
1992); lane 4, fibroblasts of NF138-3; lane 5, fibroblasts of NF134-3; lane 7, fibroblasts from a healthy donor (FC4); lane 8, fibroblasts from
a peripheral nerve of a healthy donor (N21). The densitometric units (100%p median of the values of the four controls) are as follows—FC7:
lane 2, 240 (108%), and lane 6, 218 (98%); FC4: 223 (100%); NF71: 126 (57%); NF138-3: 86 (37%); NF134-3: 126 (57%); peripheral nerve
cells (300 mg protein): 104 (47%, corresponding to 94% for 600 mg protein). B, Detection of p120GAP by western blotting. Equal amounts
of total protein (20 mg) were separated with SDS-PAGE and were blotted on PVDF membrane. Immunodetection was performed by incubation
with anti-p120GAP antibody (G12920; Transduction Laboratories) for 2 h, followed by detection with the ECL system. The densitometric units
are as follows—FC7: lane 2, 263 and lane 6, 212; FC4: 234; NF71: 268; NF138-3: 204; NF134-3: 202; peripheral nerve cells: 220.C, Investigation
of shortened neurofibromin by western blotting of immunoprecipitated neurofibromin, using sc-68. Lane 1, FC7; lane 3, NF134-3; lane 5,
NF138-3; lane 7, NF71. To evaluate unspecific signals, sc-68 was preincubated with the corresponding peptide (lanes 2, 4, 6, and 8), and the
same detection was performed. 240 kD: neurofibromin; 110 kD: unspecific product. The expected neurofibromin should be detected at ∼225
kD.
quencing of the altered fragments (Fahsold et al. 2000).
With this method we are able to recognize 170% of
NF1 mutations (data not shown). The screening for
NF2 mutations was performed by means of genomic
sequencing (Kehrer-Sawatzki et al. 1997). Fibroblasts
were isolated from the skin of the index patients and
were cultured as described by Kaufmann et al. (1999).
In NF134-3, the cells were obtained from the right
upper arm, and in NF138-3 they were obtained from
the shoulder. In addition, peripheral blood cells from
members of the families (NF134-1/2/3 and NF138-2/
3/4/5) were investigated.
In both families, NF1 mutations could be character-
ized. In the first family, in NF134-3, only one altered
fragment was detected by EMD. Through sequencing of
gDNA, a base exchange was found in NF1 exon 33
(T6200C). Investigation of !1,000 other patients with
NF1 did not reveal this base exchange in any of the
patients, indicating that it is not a polymorphism.
Screening for the NF2 mutation showed no alterations
in NF134-3. The NF1 mutation has no impact on the
amount of NF1 mRNA in cultured cells of NF134-3.
The amount of NF1 mRNA was measured in three in-
dependent experiments by quantitative competitive re-
verse-transcriptase PCR (RT-PCR) using internal stan-
dard NF1 RNA, as described in detail by Kaufmann et
al. (1999). The resulting measurement was 87.4%
of that found in the fibroblasts of a healthy donor,8.2%
as shown in a typical experiment (fig. 1A and B). To
rule out significant variation of the amount of RNA, the
expression of S14 (encoding ribosomal subunit protein)
was measured using the same method. The mRNA
amount of S14 in NF134-3 was 78.7% of that found
in the control, FC16 (fig. 1C and D). Correction of the
NF134-3 NF1 mRNA amount for the S14 mRNA
amount results in 111%. This indicates that the mRNA
transcribed from the mutated NF1 allele is stable. In-
terestingly, the change of leucine to proline at position
2067 of neurofibromin reduces the stability of the pro-
tein. This was shown by investigating the amount of
total neurofibromin in cultured cells of NF134-3 in com-
parison with controls, as described by Griesser et al.
(1997) and Klose et al. (1998). In three independent
experiments, neurofibromin was found to be reduced to
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Figure 3 NF1 mutations in family NF134 (A) and family NF138 (B). In the pedigrees, blackened symbols denote affected individuals,
unblackened symbols denote unaffected indivuals, and unblackened symbols with a blackened circle denote carriers. A, Detection of the TrC
mutation in NF1 exon 33 in family NF134. gDNA was amplified using PCR primers ex33mut (5′-TTT TAG CAC GCT ACA TGC TGG TGC)
and ex33r (5′-TTT TGG TAA TAT TTC ATG TCA TTA CTG). Primer ex33mut was designed such that an additional NlaIV restriction site
is created if the TrC mutation is present. Lanes b and c show the PCR product derived from gDNA of a healthy donor, both uncut (335 bp)
and restricted with NlaIV, respectively. Lane d shows PCR products derived from the index patient (NF134-3), lane e from her father (NF134-
1), and lane f from her mother (NF134-2), cut with NlaIV. The lower band (313 bp) in lanes d and e demonstrates the presence of the TrC
mutation in the index patient and in her father. Lane a shows a size marker. B, Detection of ArG exchange in NF1 intron 31 in family NF138.
gDNA PCR products including NF1 exon 32, using the primers ex32h (5′-TGA CAG GCC TGT AAA TAA AAT CTA G) and ex32r (5′-TTT
CCA GAA GCC AAA ACT ACA G) are shown, from a healthy control (lane b), the index patient (NF138-3, lane c), the mother (NF138-2,
lane d), her brother (NF138-4, lane e), and her sister (NF138-5, lane f), all restricted with AluI; lane a shows a 100-bp ladder (200-bp and
300-bp bands). The upper band corresponds to the wild-type PCR product of 225 bp. The lower band (144 bp) seen in lanes c and d results
from the restriction at an additional AluI site created by the mutation in intron 31. The index patient and her mother carry this NF1 mutation.
of the amount in control cells. A typical51.9% 5.4%
experiment is shown in figure 2A. As a control, the
amount of p120GAP was measured (fig. 2B). Truncated
neurofibromin was found neither in immunoprecipita-
tion of lysates from 35S-cysteine-methionin–labelled fi-
broblasts, using an antibody against the amino-terminal
domain of neurofibromin (data not shown), nor in im-
munoprecipitation and western blotting using this an-
tibody (fig. 2C). This shows that the NF1 germline mu-
tation of NF134-3 is a null mutation at the protein level
of the investigated cells, suggesting a functional hap-
loinsufficiency. The parents were investigated for this
mutation, by restriction analysis of PCR products from
gDNA (fig. 3A). Unexpectedly, her father (NF134-1),
clinically unaffected and aged 61 years, also showed this
NF1 mutation in his blood cells. Additional molecular
investigations of other tissues, to exclude a mosaicism,
were not feasible, and additional clinical investigations
through MRI scans could not be performed. Therefore,
nonpenetrance of this NF1 mutation cannot be ruled
out.
With regard to the second family (NF138), an NF1
alteration was found by EMD in the cDNA of the index
patient (NF138-3). Genomic sequencing of the corre-
sponding fragment showed a base exchange in the NF1
splice-acceptor site of exon 31 (intron 31 AACTAG/
exon32). This mutation (IVS31-5ArG) creates a new
splice-acceptor site (intron 31 AGCTAG/exon32 [base
change underlined]). The new splice site is indeed used
in cultured fibroblasts of NF138-3, as shown by se-
quencing of RT-PCR products. This results in the inser-
tion of four bases in NF1 exon 32 (exon 31 GGGCAG/
CTAG exon 32) and, subsequently, in a premature
termination codon at amino acid (aa) 1995 (exon 32).
The amount of the mutated NF1 mRNA was not re-
duced, as shown by quantitative RT-PCR. The amount
of NF1 mRNA measured was 71% of that found in the
control FC16 (fig. 1A and B). Standardized to the ex-
pression of S14 (50.4% of that in cells of the control;
fig. 1C and D), the NF1 mRNA amount in cells of
NF138-3 is 141%. At the protein level, this NF1 mu-
tation also resulted in instability of the mutated neu-
rofibromin; a reduction to 37% of the control level was
measured in the cells of NF138-3 (fig. 2A and B). Again,
a truncated neurofibromin was not detected (fig. 2C).
To test for the presence of this mutation in other mem-
bers of this family, gDNA was investigated by restriction
analysis. The base change ArG creates a new restriction
site for AluI. Restriction of PCR products obtained from
gDNA of blood cells with this enzyme resulted in an
additional shortened DNA fragment in the index patient
(NF138-3) and in her mother (NF138-2) (fig. 3B). Since
the mother’s tumors involve all segments of the spine
and the mutation was found in peripheral blood cells,
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we suggest that the NF1 mutation in NF138-2 occurred
in the germline. In this case, the clinical differences be-
tween NF138-2 and her daughter (NF138-3) suggest a
variable expressivity of this mutation.
It is assumed that most germline mutations in NF1
result in haploinsufficiency through the reduction of neu-
rofibromin levels (Heim et al. 1995; Hoffmeyer et al.
1995; Fahsold et al. 2000), which then causes NF1. We
have demonstrated that the NF1 mutations reported
here also result in reduction of neurofibromin in our
patients with spinal tumors. In both cases, the mutant
NF1 mRNAs are stable, whereas the mutant neurofi-
bromin is unstable. This is also known to occur for other
NF1 mutations. For example, patient NF71 in the study
by Stark et al. (1992) showed equal expression of the
NF1 alleles and a normal amount ofNF1mRNA (Kauf-
mann et al. 1999) but a level of neurofibromin that was
reduced by half (fig. 2A, lane 3).
Our patients do not fit the current strict clinical criteria
for SNF, because they show multiple spinal tumors but
no cafe´-au-lait macules.We assume that the investigation
of additional families that have spinal tumors and show
NF1 mutations will help to define additional criteria for
this disease that would permit the inclusion of our
patients.
Our observation is not consistent with the assump-
tion that the type or effect of the NF1 mutation can
be invoked to explain the special phenotype of SNF.
This is especially true with regard to the NF1 mutation
IVS31-5ArG in family NF138, which we detected in
an earlier study, in an unrelated patient showing clas-
sical NF1 (Fahsold et al. 2000). In the family reported
by Ars et al. (1998), SNF was described to have been
the result of a residual function of the truncated neu-
rofibromin. However, it was not demonstrated that the
truncated protein was, in fact, present in cells of the
patients in vivo. Furthermore, among mutations found
in patients with regular NF1, premature termination
codons in the same region are quite frequent—for ex-
ample, at aa 2604, 2640, 2643, and 2717 (Fahsold et
al. 2000). In our two patients, theNF1mutations result
in a reduction of neurofibromin levels, with no phe-
notypic difference in comparison with other patients
with NF1. To explain the specific phenotype of our
index patients, which represents only a small portion
of the spectrum of NF1 symptoms, we speculate that
an unknown modifying gene may be having an effect.
This modifying gene should compensate for the ma-
jority, but not all, of the effects caused by neurofi-
bromin deficiency in the cells of these patients.
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